AUS
NZ
UK
CA
USA
IND
Health
Merck (NYSE:MRK) In The S&P 500 Index Leading Biopharma With Key Products
February 26, 2026 12:00 AM PST| By Anmol KhazanchiMerck & Co. (NYSE:MRK) is a global leader in biopharmaceuticals, with strong financial performance and a significant role in the S&P 500 Index. Its focus on oncology, vaccines, and R&D positions it for continued market leadership.
-Copy_02_19_2025_19_14_16_993300.jpg)
Merck Company Inc (NYSE:MRK) Healthcare Strength In Russell 1000 index
February 25, 2026 01:14 PM PST| By Anmol KhazanchiMerck & Co., Inc. operates within the global biopharmaceutical sector, focusing on the discovery, development, manufacturing, and distribution of prescription medicines, vaccines, biologic therapies, and animal health products.
Universal Health Services (NYSE:UHS) Valuation After Pressure Now Matters To S&P 500
February 25, 2026 11:12 AM PST| By Anmol KhazanchiUniversal Health Services sits in the healthcare services sector, with operations spanning acute care hospitals and behavioural health facilities across multiple regions.
Axsome (NASDAQ:AXSM) Reaches New Heights In The Nasdaq Index Fund
February 25, 2026 12:00 AM PST| By Anmol KhazanchiAxsome Therapeutics (NASDAQ:AXSM) has gained institutional support and market attention, with strong growth in its CNS-focused pipeline. As part of the Nasdaq Index Fund, it remains a key player in biopharma.
Arvinas (NASDAQ:ARVN) Moves Higher In Nasdaq Futures With Promising Pipeline
February 25, 2026 12:00 AM PST| By Anmol KhazanchiArvinas (NASDAQ:ARVN), a leader in targeted protein degradation therapies, progresses in clinical trials and attracts market interest. As part of Nasdaq Futures, it remains a key player in biopharmaceutical innovation.
Merck (NYSE:MRK) Hits Annual High in Russell 1000
February 23, 2026 02:56 PM PST| By Anmol KhazanchiMerck reports strong quarterly results, announces oncology unit restructuring, and advances pipeline developments while trading near highs within the Russell 1000 index.
Eli Lilly (NYSE:LLY) Development Updates Drive Buzz As S&P 500 Futures
February 23, 2026 12:33 PM PST| By Anmol KhazanchiEli Lilly operates in the healthcare sector as a global pharmaceutical manufacturer with commercial medicines and a broad research portfolio across immunology, oncology, and metabolic health.
Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Strong Share Momentum
February 23, 2026 10:51 AM PST| By Anmol KhazanchiTeva Pharmaceutical Industries operates in the pharmaceuticals sector, with a business mix spanning generic medicines, select branded medicines, and complex therapies that require advanced manufacturing.
NeoGenomics (NASDAQ:NEO) Gains Traction In Nasdaq Index Mid-Cap Healthcare
February 23, 2026 12:00 AM PST| By Anmol KhazanchiNeoGenomics (NASDAQ:NEO) exceeded quarterly expectations, reinforcing valuation discussion as institutional activity and broader Nasdaq index sentiment shape trading dynamics.
Oscar Health (NYSE:OSCR) Slides on NYSE Composite Indices Earnings
February 22, 2026 01:04 PM PST| By Anmol KhazanchiOscar Health developments on the NYSE Composite reflect ownership shifts, mixed research coverage, and earnings updates across the competitive technology driven insurance market.
Select Medical (NYSE:SEM) Facing Market Pressure After Sector Weakness Hits Healthcare
February 20, 2026 11:25 AM PST| By Anmol KhazanchiThe healthcare services sector plays a crucial role in supporting patients recovering from complex illnesses, surgical procedures, and physical injuries. Companies operating in this space often manage specialized hospitals.
Pediatrix (NYSE:MD) Slips on EPS Miss; NYSE Composite Reaction
February 20, 2026 10:08 AM PST| By Anmol KhazanchiPediatrix Medical Group posts quarterly earnings below expectations with stable liquidity and ongoing clinical expansion as part of the NYSE Composite healthcare segment.
Is Xenon Pharmaceuticals (NASDAQ:XENE) Rising In The Nasdaq Index
February 20, 2026 12:00 AM PST| By Team Kalkine MediaXenon Pharmaceuticals Inc. (NASDAQ:XENE) draws attention amid institutional activity, valuation benchmarks, and broader nasdaq index market momentum.
Alvotech (NASDAQ:ALVO) Faces Valuation Reset As Nasdaq Futures Turn
February 20, 2026 12:00 AM PST| By Anmol KhazanchiAlvotech (NASDAQ:ALVO) faces rating adjustment amid broader biotech momentum shaped by Nasdaq Futures and exchange-wide liquidity trends.
Is AtriCure (NASDAQ:ATRC) Facing New Pressure In The Nasdaq Index?
February 20, 2026 12:00 AM PST| By Anmol KhazanchiAtriCure (NASDAQ:ATRC) faces brokerage downgrade while Nasdaq Index activity influences medical device sector valuation and trading tone.
Is Nuvalent (NASDAQ:NUVL) Entering a Key Phase With Nasdaq Index Fund
February 20, 2026 12:00 AM PST| By Anmol KhazanchiNuvalent (NASDAQ:NUVL) draws attention as brokerage consensus and institutional activity align with Nasdaq Index Fund biotechnology momentum.
How Medtronic (NYSE:MDT) Reacts To Market Sentiment In S&P 500 Futures
February 20, 2026 12:00 AM PST| By Anmol KhazanchiMedtronic (NYSE:MDT) excels in medical technology, with a diverse portfolio and innovation driving growth. Its performance impacts the S&P 500 futures and shapes healthcare's future.
AbbVie (NYSE:ABBV) At Midday As Traders Watch Nyse Composite Closely
February 19, 2026 04:06 PM PST| By Anmol KhazanchiAbbVie operates in the health care sector, within the biopharmaceutical space where research, regulatory progress, manufacturing reliability, and commercial execution can all influence daily trading.
Artivion Inc (NYSE:AORT) Devices Strategy And Nyse Composite Index Sector Rotation
February 19, 2026 01:32 PM PST| By Anmol KhazanchiArtivion operates in the cardiovascular medical device sector, supplying technologies used in surgical and clinical settings that focus on the heart and major blood vessels. This area of healthcare is shaped by product quality.
Johnson and Johnson Surges in s&p 500 Spotlight
February 19, 2026 01:32 PM PST| By Anmol KhazanchiJohnson and Johnson gains attention in the s&p 500 after hitting a fresh peak, announcing manufacturing expansion, regulatory progress, and updated quarterly earnings.
